Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mycobacterium vaccae vaccine
- Development stage
- Unknown
- Lead developer
- Anhui Zhifei Longcom Biopharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Mycobacterium vaccae (brand names Vaccae, Mica, or Microcard) is a heat-killed, whole-cell biological vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. It consists of inactivated *Mycobacterium vaccae* bacteria and acts as an immunomodulator to enhance cell-mediated immunity against *Mycobacterium tuberculosis*. Originally approved in China in 2001 as an adjuvant treatment for active tuberculosis, it received expanded approval from the National Medical Products Administration (NMPA) in 2021 for the preventive treatment of individuals with latent tuberculosis infection (LTBI). The vaccine is administered via intramuscular injection and has demonstrated efficacy in reducing the progression from latent infection to active disease by stimulating Th1-type immune responses.
- Brand names
- VaccaeMicaMicrocard
- Other names
- Mycobacterium vaccae for InjectionInactivated Mycobacterium vaccae
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Mycobacterium vaccae vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mycobacterium vaccae vaccine.